Validation of the Adult ADHD Investigator Symptom Ra

Journal of Attention Disorders 14, 57-68

DOI: 10.1177/1087054709347435

Citation Report

#	Article	IF	CITATIONS
1	Open Label Pilot Study of Atomoxetine in Adults With ADHD and Substance Use Disorder. Journal of Dual Diagnosis, 2010, 6, 196-207.	0.7	14
2	Guide to Assessment Scales in Attention-deficit/Hyperactivity Disorder. , 2010, , .		6
3	Reliability and validity of the Time-Sensitive ADHD Symptom Scale in adults. Comprehensive Psychiatry, 2011, 52, 769-773.	1.5	8
4	Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD. European Neuropsychopharmacology, 2011, 21, 508-515.	0.3	59
5	Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2011, 31, 108-114.	0.7	44
6	Cognitive behaviour therapy in medication-treated adults with ADHD and persistent Symptoms: A randomized controlled trial. BMC Psychiatry, 2011, 11, 116.	1.1	179
7	Transdermal and Oral dl-Methylphenidate–Ethanol Interactions in C57BL/6J Mice: Transesterification to Ethylphenidate and Elevation of d-Methylphenidate Concentrations. Journal of Pharmaceutical Sciences, 2011, 100, 2966-2978.	1.6	10
8	Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography–tandem mass spectrometry: Application to human ethanol interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 783-788.	1.2	34
9	OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder. Expert Opinion on Pharmacotherapy, 2011, 12, 315-324.	0.9	8
10	A Physician's Guide to Helping Patients with ADHD Find Success in the Workplace. Postgraduate Medicine, 2011, 123, 60-70.	0.9	9
11	Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Current Medical Research and Opinion, 2011, 27, 2309-2320.	0.9	46
12	Symptom Dimensions of Attention Deficit Hyperactivity Disorder and Nicotine Withdrawal Symptoms. Journal of Addictive Diseases, 2012, 31, 363-375.	0.8	8
13	¿Son los estimulantes efectivos en el tratamiento de los déficits de funciones ejecutivas? Resultados de un estudio aleatorizado doble ciego sobre tratamiento con metilfenidato OROS en adultos con trastorno por déficit de atención con hiperactividad. Psiquiatria Biologica, 2012, 19, 1-8.	0.0	1
14	A Translational Approach to Evaluate the Efficacy and Safety of the Novel AMPA Receptor Positive Allosteric Modulator Org 26576 in Adult Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2012, 72, 971-977.	0.7	39
15	Depression in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): The Mediating Role of Cognitive-Behavioral Factors. Cognitive Therapy and Research, 2013, 37, 1220-1232.	1.2	57
16	Assessment of ADHD. , 2013, , 37-60.		1
17	Associations between Attention Deficit Hyperactivity Disorder Symptom Domains and DSMâ€N Lifetime Substance Dependence. American Journal on Addictions, 2013, 22, 23-32.	1.3	37
19	A 9-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD. Journal of Attention Disorders, 2014, 18, 133-144.	1.5	36

#	ARTICLE	IF	Citations
21	Cognitive remediation for neuropsychological impairment in hoarding disorder: A pilot study. Journal of Obsessive-Compulsive and Related Disorders, 2014, 3, 132-138.	0.7	24
22	Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials. Journal of Psychopharmacology, 2014, 28, 837-846.	2.0	42
23	Cognitive–behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis. Psychological Medicine, 2015, 45, 2793-2804.	2.7	76
24	ADHD diagnostic and symptom assessment scales for adults. , 2014, , 224-232.		9
25	Psychosocial treatment of ADHD in adults. , 0, , 298-306.		2
26	Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder. JAMA Psychiatry, 2015, 72, 593.	6.0	131
27	Types of adult attention-deficit hyperactivity disorder (ADHD): baseline characteristics, initial response, and long-term response to treatment with methylphenidate. ADHD Attention Deficit and Hyperactivity Disorders, 2015, 7, 115-128.	1.7	40
28	Sensory gating in adult with attention-deficit/hyperactivity disorder: Event-evoked potential and perceptual experience reports comparisons with schizophrenia. Biological Psychology, 2015, 107, 16-23.	1.1	32
29	Reliability and validity of ADHD diagnostic criteria in the Assessment System for Individuals with ADHD (ASIA): a Japanese semi-structured diagnostic interview. BMC Psychiatry, 2015, 15, 130.	1.1	13
30	Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Therapeutic Advances in Psychopharmacology, 2016, 6, 317-334.	1.2	33
31	A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. Journal of Psychopharmacology, 2016, 30, 444-458.	2.0	24
32	Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder. Expert Opinion on Investigational Drugs, 2016, 25, 463-474.	1.9	24
33	Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study. Journal of Attention Disorders, 2017, 21, 1198-1207.	1.5	13
34	An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD. Journal of Attention Disorders, 2017, 21, 27-39.	1.5	23
35	Perceived social support in adults with autism spectrum disorder and attentionâ€deficit/hyperactivity disorder. Autism Research, 2017, 10, 866-877.	2.1	19
36	Psychometric properties of the Japanese version of the Adult Attention-deficit hyperactivity disorder (ADHD) Self-Report Scale (ASRS-J) and its short scale in accordance with DSM-5 diagnostic criteria. Research in Developmental Disabilities, 2017, 63, 59-66.	1.2	41
37	ADHD and Anxiety: Clinical Significance and Treatment Implications. Current Psychiatry Reports, 2017, 19, 109.	2.1	75
38	Mixed-amphetamine salts expectancies among college students: Is stimulant induced cognitive enhancement a placebo effect?. Drug and Alcohol Dependence, 2017, 178, 302-309.	1.6	26

#	ARTICLE	IF	CITATIONS
39	A randomized controlled trial reporting functional outcomes of cognitive–behavioural therapy in medication-treated adults with ADHD and comorbid psychopathology. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 267-276.	1.8	43
40	The efficacy of cognitive–behavioral therapy for older adults with ADHD: a randomized controlled trial. ADHD Attention Deficit and Hyperactivity Disorders, 2018, 10, 223-235.	1.7	23
41	How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. Drug and Alcohol Dependence, 2018, 188, 135-140.	1.6	21
42	Investigating Resilience to Depression in Adults With ADHD. Journal of Attention Disorders, 2018, 22, 497-505.	1.5	19
43	How Informative Are Self-Reported Adult Attention-Deficit/Hyperactivity Disorder Symptoms? An Examination of the Agreement Between the Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale V1.1 and Adult Attention-Deficit/Hyperactivity Disorder Investigator Symptom Rating Scale. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 339-349.	0.7	18
44	Treatment of Comorbid Adult Attention-deficit/Hyperactivity Disorder and Generalized Anxiety Disorder. Journal of Psychiatric Practice, 2018, 24, 292-298.	0.3	2
45	Are Adult ADHD Patients Good Informants of Their Symptoms? A Qualitative Literature Review of Concordance Between Clinician and Self-Report ADHD Symptoms. Journal of Nervous and Mental Disease, 2018, 206, 739-743.	0.5	7
46	ESCAlate – Adaptive treatment approach for adolescents and adults with ADHD: study protocol for a randomized controlled trial. Trials, 2018, 19, 280.	0.7	4
47	Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. International Journal of Neuropsychopharmacology, 2018, 21, 997-1006.	1.0	11
48	Validation of the French Version of the Weiss Functional Impairment Rating Scale–Self-Report in a Large Cohort of Adult Patients With ADHD. Journal of Attention Disorders, 2019, 23, 1148-1159.	1.5	7
49	Visual attention in adults with attention-deficit/hyperactivity disorder before and after stimulant treatment. Psychological Medicine, 2019, 49, 2617-2625.	2.7	8
50	Pilot Study of Droxidopa With Carbidopa in Adults With ADHD. Journal of Attention Disorders, 2019, 23, 189-198.	1.5	10
51	Validation of the Expanded Versions of the Adult ADHD Self-Report Scale v1.1 Symptom Checklist and the Adult ADHD Investigator Symptom Rating Scale. Journal of Attention Disorders, 2019, 23, 1101-1110.	1.5	27
52	Psychometric Properties of the Weiss Functional Impairment Rating Scale: Evidence for Utility in Research, Assessment, and Treatment of ADHD in Emerging Adults. Journal of Attention Disorders, 2020, 24, 1648-1660.	1.5	50
53	The Relationship Between Executive Function Deficits and <i>DSM</i> -5-Defined ADHD Symptoms. Journal of Attention Disorders, 2020, 24, 41-51.	1.5	82
54	Informativeness of Self-Reports of ADHD Symptoms in Monitoring Response to Stimulant Treatment in Clinically Referred Adults With ADHD. Journal of Attention Disorders, 2020, 24, 420-424.	1.5	5
55	A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder. World Journal of Biological Psychiatry, 2020, 21, 274-290.	1.3	8
56	Early childhood infections, antistreptococcal and basal ganglia antibodies in adult ADHD: a preliminary study. BMC Psychiatry, 2020, 20, 542.	1.1	2

#	Article	IF	Citations
57	Diagnostic delay in <scp>ADHD</scp> : Duration of untreated illness and its socioâ€demographic and clinical predictors in a sample of adult outpatients. Microbial Biotechnology, 2021, 15, 957-965.	0.9	14
58	Feasibility, Acceptability, and Effectiveness of a New Cognitive-Behavioral Intervention for College Students with ADHD. Journal of Attention Disorders, 2021, 25, 2068-2082.	1.5	18
59	Differential implications of persistent, remitted, and late-onset ADHD symptoms for substance abuse in women and men: A twin study from ages 11 to 24. Drug and Alcohol Dependence, 2020, 212, 107947.	1.6	11
60	Age and Gender Measurement Noninvariance of the Adult ADHD Self-Report Scale Screener. Journal of Attention Disorders, 2021, 25, 403-413.	1.5	1
61	Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naÃ-ve adult ADHD patients. European Neuropsychopharmacology, 2021, 46, 83-92.	0.3	4
62	Effects of methylphenidate on mismatch negativity and P3a amplitude of initially psychostimulant-naÃ-ve, adult ADHD patients. Psychological Medicine, 2021, , 1-9.	2.7	3
63	ADHD in adults with recurrent depression. Journal of Affective Disorders, 2021, 295, 1153-1160.	2.0	17
64	Adult attention-deficit hyperactivity disorder: From clinical reality toward conceptual clarity. Industrial Psychiatry, 2021, 30, 23.	0.3	3
65	ADHD in Adolescents (Middle and High School). , 2013, , 11-24.		1
66	Pharmacotherapy. , 2013, , 75-86.		2
67	Evidence of A Pharmacological Dissociation Between The Robust Effects of Methylphenidate on Adhd Symptoms and Weaker Effects on Working Memory. Journal of Brain Sciences, 2015, 1, 43-53.	1.0	4
69	Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD. Journal of Clinical Psychiatry, 2018, 79, 19-25.	1.1	7
70	Effectiveness of Parents-Focused Cognitive-Behavioral Therapy on Attention Deficit Hyperactivity Disorder Symptoms, Obesity and Self-Esteem of Overweight Children with Attention Deficient Hyperactivity Disorder. Advanced Biomedical Research, 2018, 7, 73.	0.2	8
71	Future Directions for Practice and Research. , 2013, , 87-99.		0
72	The Mixed Opioid Receptor Antagonist Naltrexone Mitigates Stimulant-Induced Euphoria. Journal of Clinical Psychiatry, 2018, 79, 17m11609.	1.1	4
74	Our current understanding of adult ADHD. Innovations in Clinical Neuroscience, 2014, 11, 30-5.	0.1	0
75	12. Instruments d'évaluation. , 2014, , 96-108.		0
76	Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. Nordic Journal of Psychiatry, 2023, 77, 102-107.	0.7	2

#	Article	IF	CITATIONS
77	Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2022, 42, 429-439.	0.7	7
78	A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs, 2022, 36, 897-915.	2.7	16
79	Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day. Journal of Child and Adolescent Psychopharmacology, 2023, 33, 14-19.	0.7	1
81	12. Instruments d'évaluation. , 2023, , 96-108.		0